Cartesian Therapeutics Inc
NASDAQ:RNAC
Cartesian Therapeutics Inc
NASDAQ:RNAC
Price:
6.18
USD
0.49%
Market Closed
Market Cap:
$163.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cartesian Therapeutics Inc
NASDAQ:RNAC
|
US |
|
C
|
Concorde International Group Ltd
NASDAQ:CIGL
|
SG |
|
V
|
Voyager Technologies Inc
NYSE:VOYG
|
US |
|
China Express Airlines Co Ltd
SZSE:002928
|
CN |
|
F
|
Frey SA
PAR:FREY
|
FR |
|
B
|
Blender Financial Technologies Ltd
TASE:BLND
|
IL |
|
S
|
SRV Yhtiot Oyj
OMXH:SRV1V
|
FI |
|
Immuron Ltd
ASX:IMC
|
AU |
|
H
|
Hcd Investment Producing and Trading JSC
VN:HCD
|
VN |
|
V
|
Vibropower Corporation Ltd
SGX:BJD
|
SG |
|
Eprice SpA
MIL:EPR
|
IT |
|
B
|
Bioalpha Holdings Bhd
KLSE:BIOHLDG
|
MY |
|
M
|
Milae Bioresources Co Ltd
KOSDAQ:218150
|
KR |
|
Formosa Petrochemical Corp
TWSE:6505
|
TW |
|
U
|
UnitedHealth Group Inc
XETRA:UNH
|
US |
|
Wt Financial Group Ltd
ASX:WTL
|
AU |
|
J W Mays Inc
NASDAQ:MAYS
|
US |
|
Indo National Ltd
NSE:NIPPOBATRY
|
IN |
|
Indel B SpA
MIL:INDB
|
IT |
|
C
|
Capstone Green Energy Corp
F:TBN2
|
US |
|
Item 9 Labs Corp
OTC:INLB
|
US |
|
D
|
Duk San Neolux Co Ltd
KOSDAQ:213420
|
KR |
|
B
|
Balurghat Technologies Ltd
BSE:520127
|
IN |
|
T
|
Tel-Instrument Electronics Corp
OTC:TIKK
|
US |
Balance Sheet
Balance Sheet Decomposition
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Balance Sheet Decomposition is not available for
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Balance Sheet
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
17
|
32
|
59
|
71
|
37
|
90
|
139
|
114
|
106
|
77
|
213
|
125
|
|
| Cash Equivalents |
17
|
32
|
59
|
71
|
37
|
90
|
139
|
114
|
106
|
77
|
213
|
125
|
|
| Short-Term Investments |
0
|
4
|
25
|
26
|
0
|
0
|
0
|
14
|
28
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
0
|
5
|
7
|
10
|
10
|
9
|
1
|
1
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
0
|
5
|
7
|
10
|
7
|
6
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
0
|
|
| Other Current Assets |
2
|
2
|
2
|
2
|
5
|
2
|
5
|
6
|
4
|
5
|
3
|
3
|
|
| Total Current Assets |
19
|
39
|
87
|
99
|
42
|
97
|
151
|
144
|
148
|
91
|
217
|
129
|
|
| PP&E Net |
2
|
2
|
2
|
2
|
2
|
2
|
12
|
12
|
14
|
12
|
15
|
18
|
|
| PP&E Gross |
2
|
2
|
2
|
2
|
2
|
2
|
12
|
12
|
14
|
12
|
15
|
18
|
|
| Accumulated Depreciation |
3
|
3
|
4
|
4
|
5
|
5
|
4
|
5
|
5
|
6
|
2
|
5
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
151
|
151
|
94
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
48
|
48
|
48
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
0
|
|
| Other Long-Term Assets |
1
|
2
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
2
|
7
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
48
|
48
|
48
|
|
| Total Assets |
22
N/A
|
43
+93%
|
89
+109%
|
101
+13%
|
44
-56%
|
100
+124%
|
165
+66%
|
160
-3%
|
166
+4%
|
305
+84%
|
435
+43%
|
296
-32%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
2
|
4
|
2
|
1
|
1
|
0
|
0
|
0
|
3
|
0
|
1
|
|
| Accrued Liabilities |
2
|
3
|
4
|
9
|
12
|
14
|
9
|
12
|
16
|
18
|
15
|
14
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
0
|
4
|
0
|
21
|
19
|
0
|
6
|
8
|
0
|
0
|
0
|
|
| Other Current Liabilities |
5
|
2
|
2
|
1
|
1
|
2
|
72
|
54
|
1
|
47
|
8
|
0
|
|
| Total Current Liabilities |
9
|
7
|
14
|
11
|
35
|
35
|
82
|
72
|
25
|
68
|
23
|
15
|
|
| Long-Term Debt |
5
|
12
|
8
|
21
|
0
|
0
|
25
|
20
|
18
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
16
|
7
|
|
| Other Liabilities |
2
|
3
|
13
|
17
|
15
|
56
|
77
|
45
|
29
|
361
|
403
|
401
|
|
| Total Liabilities |
16
N/A
|
22
+37%
|
34
+57%
|
49
+44%
|
50
+1%
|
91
+83%
|
183
+101%
|
137
-25%
|
72
-48%
|
445
+517%
|
442
-1%
|
423
-4%
|
|
| Equity | |||||||||||||
| Common Stock |
94
|
137
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
301
|
0
|
0
|
|
| Retained Earnings |
84
|
112
|
152
|
217
|
280
|
336
|
405
|
430
|
395
|
615
|
692
|
822
|
|
| Additional Paid In Capital |
0
|
0
|
211
|
273
|
280
|
349
|
391
|
457
|
493
|
179
|
690
|
701
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
4
|
5
|
5
|
4
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|
| Total Equity |
6
N/A
|
21
+234%
|
55
+162%
|
52
-6%
|
5
N/A
|
8
N/A
|
18
N/A
|
23
N/A
|
94
+317%
|
140
N/A
|
7
+95%
|
126
-1 756%
|
|
| Total Liabilities & Equity |
22
N/A
|
43
+93%
|
89
+109%
|
101
+13%
|
44
-56%
|
100
+124%
|
165
+66%
|
160
-3%
|
166
+4%
|
305
+84%
|
435
+43%
|
296
-32%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
0
|
0
|
1
|
1
|
1
|
3
|
4
|
4
|
5
|
5
|
26
|
26
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
